Table 1 Patients’ characteristics
From: Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Patient number | |||||
|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | |
Age at onset (yrs) | 4 | 1 | 2 | 13 | 2 |
Associated disease | JIA | JIA | JIA | TINU | JIA |
ANA | Negative | Positive | Positive | Positive | Positive |
Duration of disease (yrs) | 6 | 17 | 6 | 2 | 8 |
Previous treatments | MTX 15 mg/m2 weekly MTX + Adalimumab (20 mg every two weeks) | Infliximab (10 mg/kg iv)*, Cyclosporine (2,5–5 mg/kg/day) Adalimumab (30–40 mg every two weeks) Tocilizumab (8 mg/kg iv monthly) MTX 15 mg/m2 weekly + Tocilizumab (8 mg/kg iv monthly) | MTX 15 mg/m2 weekly MTX + Adalimumab (20 mg every two weeks) MTX + Adalimumab (20 mg weekly) MTX + Adalimumab (40 mg every two weeks) | Adalimumab (40 mg every two weeks) Adalimumab (40 mg weekly) MTX (15 mg m2) + Adalimumab (40 mg weekly) Adalimumab (40 mg weekly) + Micophenolate (750 mg + 500 mg) | MTX 15 mg/m2 MTX + Adalimumab (20 mg every two weeks) Adalimumab (20 mg every two weeks) Adalimumab (40 mg every two weeks) Adalimumab (40 mg weekly) |
Tocilizumab subcutaneous dose* | 162 mg every two weeks (4.2 mg/kg) | 162 mg every two weeks (2.2 mg/kg) | 162 mg every week (2.7 mg/kg) | 162 mg every week (2.7 mg/kg) | 162 mg every week (3.5 mg/kg) |
Side effects | none | none | mild hypertriglyceridemia | none | none |
Duration of therapy with subcutaneous tocilizumab(months) | 10 | 29 | 14 | 14 | 9 |
Remission after sc tocilizumab | 9 months | 2 years | 16 months | 17 months | never reached |
Pre-dose Tocilizumab serum concentrations(µg/mL) | 15.5 | 2.7 | 137.0 | 81.3 | 70.9 |
Other drugs** | - | - | methotrexate 5 mg per os weekly | mycophenolate 1000 mg/daily | methotrexate 10 mg weekly, prednisone 25 mg daily |